An open-label, exploratory study of the pharmacokinetic and pharmacodynamic activity of MabThera (rituximab) in combination with methotrexate in synovial tissue and in peripheral blood of patients with active rheumatoid arthritis.
Latest Information Update: 14 Apr 2022
At a glance
- Drugs Rituximab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Roche
- 09 Apr 2022 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 15 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 17 Dec 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.